Comparison of 48-week and 17-week trastuzumab on survival

Comparative study of 48-week and 17-week trastuzumab in terms of overall and disease-free survival in patients with HER2-positive breast cancer.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250412065291N3

Enrollment

200

Registered

2025-10-21

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer.

Interventions

Intervention 1: Intervention group: After identifying patients with breast cancer, a test to check HER2 status will be performed using IHC, FISH, or CISH methods. After determining the status of those

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with HER2-positive breast cancer Having consent to enter the study

Exclusion criteria

Exclusion criteria: Breast cancer patients who have concurrent kidney, liver, or heart failure Unwillingness to participate in the study Allergy to the above medications

Design outcomes

Primary

Measure	Time frame
Overall survival. Timepoint: To month. Method of measurement: From start chemotherapy to last follow up or recovery.	—

Secondary

Measure	Time frame
Progression free survival. Timepoint: To month. Method of measurement: From start chemotherapy to last follow up or partial recovery.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Shafiei

Ilam University of Medical Sciences

eshafiei1524@gmail.com+98 84 3222 3721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026